{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:05:09Z","timestamp":1793239509793,"version":"4.5.0"},"reference-count":68,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":196,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:p>This review explores the role of BRAF V600E in thyroid cancer with emphasis on its debated prognostic value, notable molecular heterogeneity, and opportunities as a therapeutic target. BRAF V600E, the most common oncogenic driver in papillary thyroid carcinoma, activates the MAPK pathway and suppresses genes involved in iodine metabolism and differentiation. While linked to adverse features and outcomes such as extrathyroidal extension, lymph node metastasis, recurrence, and mortality, its utility as an independent prognostic marker remains controversial. In solitary intrathyroidal tumors (1\u20134 cm) and low-risk microcarcinomas, BRAF V600E testing may help refine surgical decisions, though evidence is inconsistent, particularly for tumors &amp;lt;2 cm. The mutation also contributes to radioactive iodine (RAI) refractoriness, but not all BRAF-mutant tumors behave similarly. Transcriptomic and genomic heterogeneity \u2013 including differences in thyroid differentiation score, genetic co-alterations and miRNA signatures \u2013 modulates treatment response. Targeting BRAF V600E has led to novel therapeutic strategies. Selective BRAF and MEK inhibitors \u2013 including vemurafenib, dabrafenib, and selumetinib \u2013 have demonstrated efficacy in advanced thyroid cancers. The combination of dabrafenib and trametinib is FDA approved for BRAF V600E-mutant anaplastic thyroid carcinoma based on its significant survival benefits. Moreover, due to its histology-agnostic approval for solid tumors with BRAF V600E mutations, this regimen is now also indicated for papillary and poorly differentiated thyroid cancers. In addition, redifferentiation strategies using MAPK inhibitors to restore RAI avidity have shown promise, particularly in selected patients. These advances highlight the need to contextualize BRAF mutation status within a broader molecular and clinical framework to guide personalized, effective treatment strategies.<\/jats:p>","DOI":"10.1530\/etj-25-0225","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T11:53:13Z","timestamp":1765367593000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":11,"title":["BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2608-6397","authenticated-orcid":true,"given":"Garcilaso","family":"Riesco-Eizaguirre","sequence":"first","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"2026070713594581500_bib1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","article-title":"BRAF \u2013 a tumour-agnostic drug target with lineage-specific dependencies","volume":"21","author":"Hanrahan","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026070713594581500_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1535370220959657","article-title":"Prevalence of class I\u2013III BRAF mutations among 114,662 cancer patients in a large genomic database","volume":"246","author":"Owsley","year":"2021","journal-title":"Exp Biol Med"},{"key":"2026070713594581500_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jnci\/95.8.625","article-title":"BRAF mutation in papillary thyroid carcinoma","volume":"95","author":"Cohen","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2026070713594581500_bib4","first-page":"1454","article-title":"High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma","volume":"63","author":"Kimura","year":"2003","journal-title":"Cancer Res"},{"key":"2026070713594581500_bib5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Agrawal","year":"2014","journal-title":"Cell"},{"key":"2026070713594581500_bib6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/thy.2017.0102","article-title":"Updated American joint committee on cancer\/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why?","volume":"27","author":"Tuttle","year":"2017","journal-title":"Thyroid"},{"key":"2026070713594581500_bib7","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association Management Guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"2026070713594581500_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ecl.2018.11.007","article-title":"Genetic-guided risk assessment and management of thyroid cancer","volume":"48","author":"Xing","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2026070713594581500_bib9","article-title":"The prognostic power of gene mutations in thyroid cancer","volume":"13","author":"Ahmadi","year":"2024","journal-title":"Endocr Connect"},{"key":"2026070713594581500_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026070713594581500_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.8167","article-title":"Meta-analysis as evidence: building a better pyramid","volume":"312","author":"Berlin","year":"2014","journal-title":"JAMA"},{"key":"2026070713594581500_bib12","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1210\/jc.2008-0607","article-title":"BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713594581500_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1507\/endocrj.K08E-208","article-title":"BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients","volume":"56","author":"Yasuhiro","year":"2009","journal-title":"Endocr J"},{"key":"2026070713594581500_bib14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"key":"2026070713594581500_bib15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2017.74.5497","article-title":"Patient age-associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer","volume":"36","author":"Shen","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070713594581500_bib16","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2018.78.5097","article-title":"BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer","volume":"36","author":"Wang","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070713594581500_bib17","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1210\/clinem\/dgab286","article-title":"BRAF V600E status sharply differentiates lymph node metastasis-associated mortality risk in papillary thyroid cancer","volume":"106","author":"Tao","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713594581500_bib18","doi-asserted-by":"crossref","first-page":"E2638","DOI":"10.1210\/clinem\/dgac127","article-title":"Letter to the editor from Boucai and tuttle: \u201cBRAF V600E status sharply differentiates lymph node metastasis-associated mortality risk in papillary thyroid cancer\u201d","volume":"107","author":"Boucai","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713594581500_bib19","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/S1470-2045(25)00399-7","article-title":"Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study","volume":"26","author":"Xing","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026070713594581500_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO.2014.56.8253","article-title":"Association between BRAF V600E mutation and recurrence of papillary thyroid cancer","volume":"33","author":"Xing","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026070713594581500_bib21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa2111953","article-title":"Thyroidectomy without radioiodine in patients with low-risk thyroid cancer","volume":"386","author":"Leboulleux","year":"2022","journal-title":"N Engl J Med"},{"key":"2026070713594581500_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1071775","article-title":"Validation of dynamic risk stratification and impact of BRAF in risk assessment of thyroid cancer, a nation-wide multicenter study","volume":"13","author":"P\u00e9rez-Fern\u00e1ndez","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026070713594581500_bib23","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026070713594581500_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1530\/ERC-16-0402","article-title":"A six-genotype genetic prognostic model for papillary thyroid cancer","volume":"24","author":"Shen","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"2026070713594581500_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2026070713594581500_bib26","doi-asserted-by":"crossref","first-page":"e2327","DOI":"10.1210\/clinem\/dgae903","article-title":"Approach to the patient with thyroid cancer: selection and management of candidates for lobectomy","volume":"110","author":"Robenshtok","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713594581500_bib27","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1210\/jc.2012-1775","article-title":"The BRAFV600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-Institution results from a large cohort study","volume":"97","author":"Elisei","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713594581500_bib28","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jnci\/djx227","article-title":"BRAF V600E mutation-assisted risk stratification of solitary intrathyroidal papillary thyroid cancer for precision treatment","volume":"110","author":"Huang","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2026070713594581500_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/jnci\/djx210","article-title":"Thyroid cancer: is it all in the genes?","volume":"110","author":"Kebebew","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2026070713594581500_bib30","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/cen.12386","article-title":"The BRAFV600E mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?","volume":"80","author":"Walczyk","year":"2014","journal-title":"Clin Endocrinol"},{"key":"2026070713594581500_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7819-11-291","article-title":"The relationship between the BRAFV600E mutation in papillary thyroid microcarcinoma and clinicopathologic factors","volume":"11","author":"Choi","year":"2013","journal-title":"World J Surg Oncol"},{"key":"2026070713594581500_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1530\/ERC-14-0531","article-title":"BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis","volume":"22","author":"Li","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"2026070713594581500_bib33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1089\/thy.2015.0391","article-title":"BRAFV600E is correlated with recurrence of papillary thyroid microcarcinoma: a systematic review, multi-institutional primary data analysis, and meta-analysis","volume":"26","author":"Chen","year":"2016","journal-title":"Thyroid"},{"key":"2026070713594581500_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejca.2019.10.017","article-title":"BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma","volume":"124","author":"Kim","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026070713594581500_bib35","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1210\/jc.2019-00431","article-title":"Genomic and transcriptomic characterization of papillary microcarcinomas with lateral neck lymph node metastases","volume":"104","author":"Perera","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713594581500_bib36","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1210\/jc.2005-0987","article-title":"BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer","volume":"90","author":"Xing","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713594581500_bib37","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/0008-5472.CAN-14-3547","article-title":"The miR-146b-3p\/PAX8\/NIS regulatory circuit modulates the differentiation phenotype and function of thyroid cells during carcinogenesis","volume":"75","author":"Riesco-Eizaguirre","year":"2015","journal-title":"Cancer Res"},{"key":"2026070713594581500_bib38","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1210\/clinem\/dgab851","article-title":"Characterization of subtypes of BRAF-mutant papillary thyroid cancer defined by their thyroid differentiation score","volume":"107","author":"Boucai","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713594581500_bib39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1530\/ERC-21-0017","article-title":"Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers","volume":"28","author":"Luckett","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"2026070713594581500_bib40","doi-asserted-by":"crossref","first-page":"8317","DOI":"10.1158\/0008-5472.CAN-09-1248","article-title":"The BRAFV600E oncogene induces transforming growth factor \u03b2 secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer","volume":"69","author":"Riesco-Eizaguirre","year":"2009","journal-title":"Cancer Res"},{"key":"2026070713594581500_bib41","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1158\/1078-0432.CCR-22-2882","article-title":"Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy","volume":"29","author":"Boucai","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026070713594581500_bib42","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1172\/JCI46382","article-title":"Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation","volume":"121","author":"Chakravarty","year":"2011","journal-title":"J Clin Investig"},{"key":"2026070713594581500_bib43","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/1078-0432.CCR-11-0563","article-title":"Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements","volume":"18","author":"Hayes","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026070713594581500_bib44","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N Engl J Med"},{"key":"2026070713594581500_bib45","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.21.00714","article-title":"Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: a phase III, randomized, placebo-controlled trial (ASTRA)","volume":"40","author":"Ho","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026070713594581500_bib46","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/thy.2022.0707","article-title":"Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy","volume":"33","author":"Wadsley","year":"2023","journal-title":"Thyroid"},{"key":"2026070713594581500_bib47","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2967\/jnumed.122.264913","article-title":"The role of pretherapy quantitative imaging and dosimetry in radioiodine therapy for advanced thyroid cancer","volume":"64","author":"Taprogge","year":"2023","journal-title":"J Nucl Med"},{"key":"2026070713594581500_bib48","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1089\/thy.2013.0057","article-title":"Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAFV600E mutation","volume":"23","author":"Kim","year":"2013","journal-title":"Thyroid"},{"key":"2026070713594581500_bib49","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070713594581500_bib50","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026070713594581500_bib51","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","article-title":"Anti-programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial","volume":"10","author":"Cabanillas","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026070713594581500_bib52","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1210\/jc.2018-01478","article-title":"Vemurafenib redifferentiation of BRAF mutant, rai-refractory thyroid cancers","volume":"104","author":"Dunn","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713594581500_bib53","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas","volume":"3","author":"Montero-Conde","year":"2013","journal-title":"Cancer Discov"},{"key":"2026070713594581500_bib54","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/thy.2021.0565","article-title":"Enhancing radioiodine incorporation in BRAF-Mutant, radioiodine-refractory thyroid cancers with vemurafenib and the Anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial","volume":"32","author":"Tchekmedyian","year":"2022","journal-title":"Thyroid"},{"key":"2026070713594581500_bib55","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-20-0735","article-title":"Swi\/snf complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies","volume":"11","author":"Saqcena","year":"2021","journal-title":"Cancer Discov"},{"key":"2026070713594581500_bib56","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"2026070713594581500_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/thy.2014.0123","article-title":"BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer","volume":"25","author":"Falchook","year":"2015","journal-title":"Thyroid"},{"key":"2026070713594581500_bib58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070713594581500_bib59","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070713594581500_bib60","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"2026070713594581500_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102447","article-title":"Dabrafenib and trametinib administration in patients with BRAF V600E\/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial","volume":"69","author":"Shimoi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026070713594581500_bib62","first-page":"1184","article-title":"Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"key":"2026070713594581500_bib63","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1078-0432.CCR-14-2915","article-title":"Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib","volume":"21","author":"Rothenberg","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026070713594581500_bib64","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","article-title":"A phase II redifferentiation trial with Dabrafenib-Trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-Mutated differentiated thyroid","volume":"29","author":"Leboulleux","year":"2023","journal-title":"Cancer Clin Cancer Res"},{"key":"2026070713594581500_bib65","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/thy.2023.0456","article-title":"Clinical outcomes of radioactive iodine redifferentiation therapy in previously iodine refractory differentiated thyroid cancers","volume":"34","author":"Toro-Tobon","year":"2024","journal-title":"Thyroid"},{"key":"2026070713594581500_bib66","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1007\/s00405-013-2872-7","article-title":"The association between BRAFV600E mutation and pathological features in PTC","volume":"271","author":"Liu","year":"2014","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2026070713594581500_bib67","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1159\/000443032","article-title":"Meta-Analyses of Association Between BRAFV600E Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma","volume":"38","author":"Zhang","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"2026070713594581500_bib68","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12957-016-0979-1","article-title":"Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis","volume":"14","author":"Liu","year":"2016","journal-title":"World J Surg Oncol"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/6\/ETJ-25-0225.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/6\/ETJ-25-0225.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0225\/506519\/etj-25-0225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0225\/506519\/etj-25-0225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:00:01Z","timestamp":1783447201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/14\/6\/e250225\/75600\/BRAF-V600E-in-thyroid-cancer-navigating-prognostic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0225","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"article-number":"e250225"}}